FLT3 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for FLT3 is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
311 Direct drug records from Target & Disease MCP | 214 Development records in target context | 490 Disease associations captured | 2343 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
FLT3 is a high-value hematologic kinase target
Target & Disease MCP profiles FLT3 as a receptor for FLT3LG that regulates differentiation, proliferation, and survival of hematopoietic progenitor and dendritic cells. Mutations that drive constitutive activity activate AKT, MTOR, RAS-MAPK, PLCG1, STAT5, and anti-apoptotic signaling, making FLT3 central in AML biology.
Validation is strong and clinically actionable
The MCP workflow retrieved 311 direct drug records, 214 development records, and 490 disease associations. Clinical Trials MCP returned 2,343 trial records, supporting a mature but still active development field around AML, resistant disease, and combinations.
Competition includes AML combinations and multikinase overlap
Recent trials include pacritinib with venetoclax and azacitidine in accelerated/blast-phase myeloproliferative neoplasms, nintedanib in idiopathic pulmonary fibrosis, and sunitinib-containing oncology combinations. This shows both FLT3-specific hematology and broader kinase overlap.
IP and strategy view
FLT3 IP should emphasize mutation coverage, resistance, combination regimens, MRD-driven use, tolerability, and differentiation from established FLT3 inhibitors.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 2343 registered trial records connected to FLT3. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| Pacritinib plus venetoclax and azacitidine in accelerated/blast-phase myeloproliferative neoplasms | Phase 1 | Not yet recruiting |
| MNKD-201 nintedanib dry powder inhalation in idiopathic pulmonary fibrosis | Phase 2 | Not yet recruiting |
| Ipalotinib/tislelizumab plus sunitinib and olaparib in HRD-positive advanced ovarian cancer | Phase 2 | Recruiting |
R&D Strategy Recommendation
FLT3 remains attractive when a program can improve on resistance, combinations, or tolerability in mutation-defined hematologic disease. Broad multikinase positioning alone is less compelling.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
